MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Kite Pharma Company Profile (NASDAQ:KITE)

Consensus Ratings for Kite Pharma (NASDAQ:KITE) (?)
Ratings Breakdown: 14 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $79.83 (67.02% upside)

Analysts' Ratings History for Kite Pharma (NASDAQ:KITE)
Show:
DateFirmActionRatingPrice TargetActions
4/24/2016FBR & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/20/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/20/2016Maxim GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/21/2016MizuhoReiterated RatingBuy$90.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/19/2016Stifel NicolausReiterated RatingBuy$63.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/18/2016Jefferies GroupReiterated RatingBuy$75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/20/2016SunTrustReiterated RatingBuy$70.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2016Citigroup Inc.Initiated CoverageBuy$67.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman SachsLower Price Target$111.00 -> $92.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/1/2016RBC CapitalInitiated CoverageOutperform$85.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/15/2015Standpoint ResearchUpgradeHold -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/3/2015Cowen and CompanyReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/14/2015GuggenheimReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2015Credit SuisseReiterated RatingOutperform$79.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/2/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha